Dual-molecular barcode sequencing detects rare variants in tumor and cell free DNA in plasma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 02 2020
25 02 2020
Historique:
received:
13
09
2019
accepted:
11
02
2020
entrez:
27
2
2020
pubmed:
27
2
2020
medline:
21
11
2020
Statut:
epublish
Résumé
Conventional next generation sequencing analysis has provided important insights into cancer genetics. However, the detection of rare (low allele fraction) variants remains difficult because of the error-prone nucleotide changes derived from sequencing/PCR errors. To eliminate the false-positive variants and detect genuine rare variants, sequencing technology combined with molecular barcodes will be useful. Here, we used the newly developed dual-molecular barcode technology (Ion AmpliSeq HD) to analyze somatic mutations in 24 samples (12 tumor tissues and 12 plasma) from 12 patients with biliary-pancreatic and non-small cell lung cancers. We compared the results between next generation sequencing analysis with or without molecular barcode technologies. The variant allele fraction (VAF) between non-molecular barcode and molecular barcode sequencing was correlated in plasma DNA (R
Identifiants
pubmed: 32099048
doi: 10.1038/s41598-020-60361-3
pii: 10.1038/s41598-020-60361-3
pmc: PMC7042261
doi:
Substances chimiques
Cell-Free Nucleic Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3391Références
McGranahan, N. & Swanton, C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell 168, 613–628 (2017).
pubmed: 28187284
doi: 10.1016/j.cell.2017.01.018
McGranahan, N. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med. 7, 283ra254 (2015).
doi: 10.1126/scitranslmed.aaa1408
Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra224 (2014).
doi: 10.1126/scitranslmed.3007094
Salk, J. J., Schmitt, M. W. & Loeb, L. A. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat. Rev. Genet. 19, 269–285 (2018).
pubmed: 29576615
pmcid: 6485430
doi: 10.1038/nrg.2017.117
Luthra, R. et al. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors. J. Mol. Diagn. 19, 255–264 (2017).
pubmed: 28017569
doi: 10.1016/j.jmoldx.2016.09.011
Mehrotra, M. et al. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. J. Mol. Diagn. 19, 514–524 (2017).
pubmed: 28506684
doi: 10.1016/j.jmoldx.2017.03.003
Demuth, C., Winther-Larsen, A., Madsen, A., Meldgaard, P. & Sorensen, B. A Method for Treatment Monitoring Using Circulating Tumour DNA in Cancer Patients Without Targetable Mutations. Oncotarget 9, 31066–31076 (2018).
pubmed: 30123427
pmcid: 6089565
doi: 10.18632/oncotarget.25779
Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. & Vogelstein, B. Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl Acad. Sci. USA 108, 9530–9535 (2011).
pubmed: 21586637
doi: 10.1073/pnas.1105422108
Newman, A. M. et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat. Biotechnol. 34, 547–555 (2016).
pubmed: 27018799
pmcid: 4907374
doi: 10.1038/nbt.3520
Schmitt, M. et al. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl Acad. Sci. USA 109, 14508–14513 (2012).
pubmed: 22853953
doi: 10.1073/pnas.1208715109
pmcid: 22853953
Corcoran, R. B. & Chabner, B. A. Application of Cell-free DNA Analysis to Cancer Treatment. N. Engl. J. Med. 379, 1754–1765 (2018).
pubmed: 30380390
doi: 10.1056/NEJMra1706174
pmcid: 30380390
Wan, J. C. M. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer 17, 223–238 (2017).
pubmed: 28233803
doi: 10.1038/nrc.2017.7
pmcid: 28233803
Amemiya, K. et al. Touch imprint cytology with massively parallel sequencing (TIC-seq): a simple and rapid method to snapshot genetic alterations in tumors. Cancer Med. 5, 3426–3436 (2016).
pubmed: 27774772
pmcid: 5224853
doi: 10.1002/cam4.950
Sakamoto, I. et al. BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer. Cancer 122, 84–90 (2016).
pubmed: 26439132
doi: 10.1002/cncr.29707
pmcid: 26439132
Hirotsu, Y. et al. Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. Mol. Genet. Genomic Med. 3, 121–129 (2015).
pubmed: 25802882
doi: 10.1002/mgg3.120
pmcid: 25802882
Iijima, Y. et al. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer. Eur. J. Cancer 86, 349–357 (2017).
pubmed: 29078173
doi: 10.1016/j.ejca.2017.09.004
pmcid: 29078173
Amemiya, K., Hirotsu, Y., Oyama, T. & Omata, M. Relationship between formalin reagent and success rate of targeted sequencing analysis using formalin fixed paraffin embedded tissues. Clin. Chim. Acta 488, 129–134 (2019).
pubmed: 30395866
doi: 10.1016/j.cca.2018.11.002
pmcid: 30395866
Goto, T., Hirotsu, Y., Oyama, T., Amemiya, K. & Omata, M. Analysis of tumor-derived DNA in plasma and bone marrow fluid in lung cancer patients. Med. Oncol. 33, 29 (2016).
pubmed: 26897174
doi: 10.1007/s12032-016-0744-x
pmcid: 26897174
Jiang, P. et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc. Natl Acad. Sci. USA 112, E1317–1325 (2015).
pubmed: 25646427
doi: 10.1073/pnas.1500076112
Goto, T. et al. Detection of tumor-derived DNA dispersed in the airway improves the diagnostic accuracy of bronchoscopy for lung cancer. Oncotarget 8, 79404–79413 (2017).
pubmed: 29108319
pmcid: 5668052
Goto, T. et al. Distribution of circulating tumor DNA in lung cancer: analysis of the primary lung and bone marrow along with the pulmonary venous and peripheral blood. Oncotarget 8, 59268–59281 (2017).
pubmed: 28938635
pmcid: 5601731
Goto, T. et al. Stepwise addition of genetic changes correlated with histological change from “well-differentiated” to “sarcomatoid” phenotypes: a case report. BMC Cancer 17, 65 (2017).
pubmed: 28103823
pmcid: 5248474
doi: 10.1186/s12885-017-3059-1
Goto, T. et al. Mutational analysis of multiple lung cancers: Discrimination between primary and metastatic lung cancers by genomic profile. Oncotarget 8, 31133–31143 (2017).
pubmed: 28415711
pmcid: 5458195
Nakagomi, T. et al. New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles. Oncotarget 9, 10635–10649 (2018).
pubmed: 29535832
pmcid: 5828205
doi: 10.18632/oncotarget.24365
Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell 32, 185–203 e113 (2017).
doi: 10.1016/j.ccell.2017.07.007
Farshidfar, F. et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep. 18, 2780–2794 (2017).
pubmed: 28297679
pmcid: 5493145
doi: 10.1016/j.celrep.2017.02.033
Jiao, Y. et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat. Genet. 45, 1470–1473 (2013).
pubmed: 24185509
pmcid: 4013720
doi: 10.1038/ng.2813
Nakamura, H. et al. Genomic spectra of biliary tract cancer. Nat. Genet. 47, 1003–1010 (2015).
pubmed: 26258846
doi: 10.1038/ng.3375
pmcid: 26258846
Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nat. 531, 47–52 (2016).
doi: 10.1038/nature16965
Scarpa, A. et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nat. 543, 65–71 (2017).
doi: 10.1038/nature21063
Jiao, Y. et al. Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. J. Pathol. 232, 428–435 (2014).
pubmed: 24293293
pmcid: 4048021
doi: 10.1002/path.4310
Yachida, S. et al. Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. Cancer Cell 29, 229–240 (2016).
pubmed: 26806338
pmcid: 5503303
doi: 10.1016/j.ccell.2015.12.012
Tate, J. G. et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 47, D941–D947 (2019).
pubmed: 30371878
doi: 10.1093/nar/gky1015
Hirotsu, Y. et al. Comparison between two amplicon-based sequencing panels of different scales in the detection of somatic mutations associated with gastric cancer. BMC Genomics 17, 833 (2016).
pubmed: 27782820
pmcid: 5080794
doi: 10.1186/s12864-016-3166-4
Hirotsu, Y. et al. Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer. Mol. Genet. Genomic Med. 3, 459–466 (2015).
pubmed: 26436112
pmcid: 4585454
doi: 10.1002/mgg3.157
Takaoka, S. et al. Molecular subtype switching in early-stage gastric cancers with multiple occurrences. J. Gastroenterol. 54, 674–686 (2019).
pubmed: 30666417
doi: 10.1007/s00535-019-01547-z
Hirotsu, Y. et al. Targeted and exome sequencing identified somatic mutations in hepatocellular carcinoma. Hepatol. Res. 46, 1145–1151 (2016).
pubmed: 26850916
doi: 10.1111/hepr.12663
Chakravarty, D. et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology (2017).
Jamal-Hanjani, M. et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
pubmed: 28445112
doi: 10.1056/NEJMoa1616288
Zhou, W. et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nat. 462, 1070–1074 (2009).
doi: 10.1038/nature08622
Thress, K. S. et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21, 560–562 (2015).
pubmed: 25939061
pmcid: 4771182
doi: 10.1038/nm.3854
Choi, Y. et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734–1739 (2010).
pubmed: 20979473
doi: 10.1056/NEJMoa1007478
Piotrowska, Z. et al. Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. JCO Precis Oncol (2018).
Morelli, M. P. et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann. Oncol. 26, 731–736 (2015).
pubmed: 25628445
pmcid: 4374387
doi: 10.1093/annonc/mdv005
Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nat. 486, 532–536 (2012).
doi: 10.1038/nature11156
Bose, R. et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 3, 224–237 (2013).
pubmed: 23220880
doi: 10.1158/2159-8290.CD-12-0349
Hirotsu, Y. et al. Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient. Med. Oncol. 34, 3 (2017).
pubmed: 27900589
doi: 10.1007/s12032-016-0857-2
Robinson, D. R. et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 1446–1451 (2013).
pubmed: 24185510
pmcid: 4009946
doi: 10.1038/ng.2823
Schiavon, G. et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci. Transl. Med. 7, 313ra182 (2015).
pubmed: 26560360
pmcid: 4998737
doi: 10.1126/scitranslmed.aac7551
Turke, A. B. et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77–88 (2010).
pubmed: 20129249
pmcid: 20129249
doi: 10.1016/j.ccr.2009.11.022
Van Emburgh, B. O. et al. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat. Commun. 7, 13665 (2016).
pubmed: 27929064
pmcid: 5155160
doi: 10.1038/ncomms13665